BioAge Labs (NASDAQ:BIOA) Research Coverage Started at Oppenheimer

Oppenheimer assumed coverage on shares of BioAge Labs (NASDAQ:BIOA) in a research report released on Wednesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $60.00 price target on the stock.

A number of other brokerages also recently commented on BIOA. Wall Street Zen upgraded shares of BioAge Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Piper Sandler initiated coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Citigroup lifted their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Finally, Morgan Stanley set a $23.00 price target on BioAge Labs in a research note on Wednesday, February 4th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioAge Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.67.

BioAge Labs Trading Down 0.2%

NASDAQ:BIOA opened at $22.27 on Wednesday. BioAge Labs has a 12-month low of $2.88 and a 12-month high of $24.00. The stock’s 50 day simple moving average is $18.29 and its 200-day simple moving average is $10.91. The firm has a market cap of $798.38 million, a P/E ratio of -14.65 and a beta of 1.42.

Insider Activity

In related news, insider Paul D. Rubin sold 7,433 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer owned 22,408 shares in the company, valued at approximately $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 354,437 shares of company stock worth $5,813,228. Company insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. acquired a new stake in BioAge Labs in the 4th quarter valued at about $3,025,000. XTX Topco Ltd purchased a new stake in shares of BioAge Labs in the fourth quarter valued at about $486,000. Sphera Funds Management LTD. acquired a new stake in shares of BioAge Labs in the fourth quarter valued at approximately $3,215,000. Quadrature Capital Ltd increased its stake in shares of BioAge Labs by 56.2% during the 4th quarter. Quadrature Capital Ltd now owns 16,769 shares of the company’s stock worth $222,000 after purchasing an additional 6,035 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of BioAge Labs during the 4th quarter worth approximately $5,406,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.